Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.91 USD
Change Today -0.18 / -2.22%
Volume 2.1M
ARIA On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (ARIA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $9.89
52 Week Low
10/13/14 - $4.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ariad pharmaceuticals inc (ARIA) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (ARIA) Details

ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories. It also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, an orally active TKI for treating non-small cell lung cancer and various other solid tumors. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

379 Employees
Last Reported Date: 03/2/15
Founded in 1991

ariad pharmaceuticals inc (ARIA) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $676.0K
Chief Scientific Officer and President of Res...
Total Annual Compensation: $858.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $683.4K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $647.0K
Compensation as of Fiscal Year 2014.

ariad pharmaceuticals inc (ARIA) Key Developments

ARIAD Pharmaceuticals Inc. Announces Encouraging Follow-Up Data from Phase I Leukemia Trial

ARIAD Pharmaceuticals Inc. has announced encouraging long-term follow-up data from the Phase I trial of Iclusig, or ponatinib, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia, or CML, or Philadelphia chromosome-positive acute lymphoblastic leukemia, or Ph+ ALL. With a median follow-up of over four years (53.1 months), Iclusig continues to demonstrate anti-leukemic activity in chronic-phase (CP) CML patients with limited treatment options (n=43). Overall, 72% of CP-CML patients achieved a major cytogenetic response (MCyR) on trial, 65% a complete cytogenetic response (CCyR) and 56% a major molecular response (MMR). Long-term safety data on ponatinib indicate that benefit-risk evaluations should guide decisions to initiate and maintain therapy, particularly in patients who may be at increased risk for arterial occlusive events. The Phase I dose-escalation study of ponatinib (dose range, 2 to 60 mg once daily) enrolled 81 patients with resistant or refractory hematologic cancers, including 43 patients with CP-CML. 60% of CP-CML patients in this study had failed at least three prior tyrosine kinase inhibitors (TKI), and 98% received at least two prior TKIs. Twenty-two CP-CML patients (51%) remain on study. Median follow-up for CP-CML patients is over 4 years (53.1 months) with a maximum follow-up of six years (69.9 months). Of 22 ongoing CP-CML patients, 14 are receiving a dose of 15 mg/day ponatinib or less, 5 on 30 mg/day, and 3 on 45 mg/day; the mean current dose is 22.5 mg/day. The median dose intensity for these patients during the course of the study was 33.7 mg/day. Anti-leukemic activity continues to be observed with ponatinib treatment: 72% of CP-CML patients achieved MCyR, 65% CCyR and 56% MMR. Of note, 77% (17/22) of ongoing CP-CML patients are in deep molecular response of MMR or better. The median times to MCyR, CCyR and MMR were 2.8, 5.5 and 7.4 months, respectively. By Kaplan-Meier estimate, the probability of CP-CML patients maintaining MCyR at 4 years was 71%. Ten of the 15 CP-CML patients (67%) who started ponatinib at a dose of 30 mg or less achieved MCyR. Of the 12 CP-CML patients with the T315I mutation enrolled in the trial, 1 discontinued; 10 of the 11 CP-CML patients with the T315I mutation who remained on study achieved MCyR, with 8 of 10 in continuous MCyR. The most common treatment-emergent adverse events (greater than or equal to 50%) occurring in CP-CML patients were rash (65%), fatigue (63%), abdominal pain (58%), headache (58%), arthralgia (53%), and constipation (51%). The most common serious treatment-emergent adverse events were abdominal pain, atrial fibrillation, myocardial infarction, and pancreatitis (n=4 each). 30% (n=13) of CP-CML patients experienced a serious arterial occlusive event (AOE); 40% (n=17) of CP-CML patients experienced an AOE of any severity. Two patients experienced a venous thromboembolic event (VTEs); no serious VTEs were observed. No patient death was attributed to an AOE or VTE. No new AOEs have been reported since study data were last reported in December 2014 (data as of September 26, 2014).

ARIAD Pharmaceuticals, Inc. Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals Inc. announced long-term follow up from its pivotal Phase 2 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3.5 years for chronic phase CML (CP-CML) patients and a median follow-up of approximately 2.9 years in all patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Responses have been maintained long-term in CP-CML patients. 83% of CP-CML patients who achieved a major cytogenetic response (MCyR) are estimated to remain in MCyR at three years. Additionally, 95% of CP-CML patients who underwent ponatinib dose reductions maintained their responses (MCyR). Benefit-risk evaluations should guide the decision to initiate and maintain Iclusig therapy, particularly in patients who may be at increased risk for arterial occlusive events (AOE). PACE Trial Update: The efficacy and safety of ponatinib in CML and Ph+ ALL patients resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation, were evaluated in the pivotal Phase 2 PACE trial. A total of 449 patients were treated with ponatinib at a starting dose of 45 mg/day. 93% of patients had previously received two or more approved tyrosine kinase inhibitors (TKI), and 55% had previously received three or more approved TKIs. Updated data on CP-CML patients (n=270) from the ongoing trial indicate that with a median follow-up of 42.3 months (data as of February 2, 2015), 114 patients (42%) continue to receive ponatinib. Additional data in CP-CML patients include: 59% of CP-CML patients achieved MCyR (primary endpoint) at any time; 83% of patients who achieved MCyR are estimated to remain in MCyR at 3 years; 39% of patients achieved a major molecular response (MMR) or better; By Kaplan-Meier analysis, progression-free survival at 3 years is estimated to be 60%; Overall survival at 3 years is estimated to be 81%; 23% of CP-CML patients experienced an AOE designated a serious adverse event (SAE), and 28% of CP-CML patients experienced any AOE. The median time to onset for AOEs in CP-CML patients was 14.1 (0.3–44.0) months; 4% and 5% of CP-CML patients, respectively experienced a venous thromboembolic SAE or AE; The most common all-grade treatment-emergent adverse events occurring in = 40% of CP-CML patients were abdominal pain (46%), rash (46%), thrombocytopenia (45%), headache (43%), constipation (41%), and dry skin (41%); the discontinuation rate due to adverse events was 18% in CP-CML.

Ariad Pharmaceuticals Inc. and Paladin Labs Inc. Announces Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada

Ariad Pharmaceuticals Inc. announced that ARIAD has granted Paladin exclusive rights to distribute Iclusig™ (as ponatinib hydrochloride) in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Health Canada recently approved Iclusig for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or Ph+ ALL that is T315I mutation positive, or where there is prior TKI resistance or intolerance. Iclusig will be made available through a controlled distribution program, whereby prescribers who have completed the certification procedure will be able to prescribe Iclusig. Under the terms of the agreement, ARIAD will continue to be the Marketing Authorization Holder of Iclusig in Canada, and Paladin will be responsible for distribution, sales and marketing, medical affairs, and pricing and reimbursement activities. Paladin will book sales of Iclusig in Canada while ARIAD will supply packaged drug to Paladin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $7.91 USD -0.18

ARIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.44 USD -0.03
Array BioPharma Inc $6.89 USD -0.13
Evotec AG €3.30 EUR -0.03
Exelixis Inc $3.44 USD -0.05
Pfizer Ltd/India 2,006 INR +4.45
View Industry Companies

Industry Analysis


Industry Average

Valuation ARIA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.9x
Price/Book 40.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at